Image Credit: STAT News
STAT+: Capricor Therapeutics forges ahead with FDA on Duchenne drug, despite political tumult
While there have been reports from drugmakers about possible interruptions with FDA matters due to staff layoffs, one company “hasn’t noticed any difference.”